SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. (Colorado) on December 13, 2012, covering events occurring on December 11 and December 12, 2012. The filing documents a special meeting of shareholders and subsequent corporate amendments. Note: The request metadata references "Riot Platforms, Inc.," but the source text explicitly identifies the registrant as AspenBio Pharma, Inc., which is changing its name to Venaxis, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and structural changes rather than financial performance metrics.
Material Changes and Corporate Actions
- Corporate Name Change: Shareholders approved an amendment to the Articles of Incorporation to change the company name from AspenBio Pharma, Inc. to Venaxis, Inc. The Articles of Amendment were filed on December 12, 2012.
- Stock Incentive Plan Expansion: Shareholders approved an amendment to the Amended and Restated 2002 Stock Incentive Plan, increasing the number of shares of Common Stock reserved under the Plan from 287,205 to 1,487,205.
- Auditor Ratification: Shareholders ratified the appointment of GHP Horwath, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2012.
Voting Results and Management Commentary
At the Special Meeting, 5,585,417 shares were represented out of 7,716,480 outstanding shares entitled to vote. The voting outcomes were as follows:
- Name Change Resolution: 5,092,081 FOR; 481,137 AGAINST; 12,199 ABSTAIN.
- Stock Plan Amendment Resolution: 1,911,059 FOR; 165,321 AGAINST; 165,909 ABSTAIN.
- Auditor Ratification Resolution: 5,526,176 FOR; 26,074 AGAINST; 33,167 ABSTAIN.
The filing contains no explicit management commentary regarding future outlook, risks, or contingencies beyond the procedural details of the shareholder approvals.
Investor Verification Checklist
- Verify the effective date and legal status of the name change to Venaxis, Inc.
- Confirm the impact of the increased stock option pool (1,487,205 shares) on potential future dilution.
- Review the full text of the Amendment to the 2002 Stock Incentive Plan (Exhibit 10.1) for specific terms.
- Check subsequent filings to confirm the ticker symbol change associated with the new corporate name.